Not Yet Recruiting
A Phase 2 Multicenter Single-Arm Clinical Trial of Zanzalintinib and Pembrolizumab in Subjects With Resectable Clear Cell Renal Cell Carcinoma
NCT07691476
- Conditions
- Patients With Locally Advanced or Metastatic But Resectable Clear Cell Renal Cell Carcinoma
- Locations
-
Not specified